Skip to content
Black Week: 20% off everything, code BLACK

Search

What are you looking for?

Type at least 2 characters to see suggestions.

MK2866 60 caps

MK2866 60 caps

MK-2866 (Ostarine, enobosarm) 10 mg × 60 capsules is a non-steroidal selective androgen receptor modulator (SARM) from the Endogenic line – the best clinically tested SARM. It binds the androgen receptor with high affinity, maintaining muscle and bone anabolism with minimal androgenic activity in the prostate – the highest documented tissue selectivity in its class. Research Use Only reagent

33,99 €
With code BLACK: 27,19 € Lowest price in the 30 days before the discount: 33,99 €
Fast shipping
Free delivery from 350 €
Returns policy

MK-2866 (Ostarine) 10 mg 60 caps - SARM research reagent

  • MK-2866 (ostarine, enobosarm): a selective androgen receptor modulator.
  • 10 mg per capsule; pack of 60 capsules.
  • Research Use Only reagent, not a medicinal product.

Product status information

Chemical reagent intended exclusively for laboratory tests (Research Use Only). It is not a medicinal product, dietary supplement or food. It is not intended for use on humans or animals. Sales only to registered research units and laboratories.

WADA STATUS – CATEGORY S1.2 (OTHER ANABOLIC AGENTS)

MK-2866 (ostarine, enobosarm) is on the World Anti-Doping Agency (WADA) Prohibited List in the category S1.2 – other anabolic agents, as a selective androgen receptor modulator (SARM). The substance is prohibited both in competition and out of competition, continuously since 2008 — was one of the first SARMs subject to an anti-doping ban and has since remained one of the most frequently detected SARMs in doping samples.

It is imperative that Registered Athletes (ADAMS) verify the current Prohibited List before making any decision – the presence of ostarine or its metabolites in a doping sample constitutes an anti-doping rule violation.

Introduction

The androgen receptor (AR) regulates muscle anabolism and bone density, but the classic androgen ligands – testosterone and anabolic-androgenic steroids – stimulate it without tissue discrimination. Muscle stimulation is then accompanied by stimulation of the prostate, skin and gonadal axis, which drives the adverse effect profile of this entire class. Selective androgen receptor modulators (SARMs) are pharmacology’s answer to this problem: molecules that were supposed to preserve the anabolic stimulation of AR in muscle and bone, while limiting activity in androgen-dependent tissues such as the prostate.

MK-2866 belongs to the Pro-Body catalog line SARMs — research reagents from the group of selective androgen receptor modulators. MK-2866 (ostarine, enobosarm, code GTx-024) is a representative of this class with the most extensive clinical documentation of all SARMs. Pro-Body supplies it in line Endogenic as a research reagent in format 10 mg × 60 capsules.

Chemically, it is a small non-steroidal molecule from the arylpropionamide group – not a steroid, despite a similar molecular attachment point. In terms of mechanism, it is a tissue-selective androgen receptor ligand: in preclinical models it behaves as a full AR agonist in muscle and bone, with minimal androgenic activity in the prostate. MK-2866 was developed by the American biopharmaceutical company GTx, and the characterization of this molecule includes a phase I–III clinical trial program for sarcopenia (age-related loss of muscle mass) and cachexia (cancer cachexia).

This makes ostarine the most clinically tested SARM – no other compound of this class has undergone such an extensive research program in humans. In research terms, ostarine remains a model tool for studying the tissue selectivity of AR ligands, muscle anabolism and bone metabolism. Purity verified by HPLC ≥98%, identity confirmed by mass spectrometry, COA available for each batch.

REGULATORY STATUS

MK-2866 is not registered as a drug in the EU or USA. The GTx clinical program (phase I-III) did not achieve a primary endpoint that fully satisfied the registration authorities, so ostarine was not authorized by the FDA or EMA. The FDA also issued Warning Letters against entities marketing SARMs as ingredients of human products. MK-2866 has been on the WADA Prohibited List in category S1.2 (other anabolic agents) continuously since 2008. Communicating the product as a “SARM for mass”, a “safer steroid” or an “anabolic without side effects” is contrary to the Research Use Only framework.

SARMs and the concept of tissue selectivity of the androgen receptor

Selective androgen receptor modulators (SARMs) are a pharmacological class identified at the turn of the 1990s and 2000s as a response to the limitations of anabolic-androgenic steroids. The starting point was the observation that the androgen receptor functions differently in different tissues – the conformation of the ligand-receptor complex and the set of recruited coregulators (coactivators and corepressors) differ between muscle, bone, prostate and skin.

The design hypothesis assumed that a structurally appropriate molecule could stimulate AR as an agonist in some tissues (muscle, bone) and act as a partial agonist or almost inactively in others (prostate). MK-2866 holds a special position in this class. It is a non-steroidal arylpropionamide – a compound whose chemical skeleton has nothing in common with the sterane ring of steroids, although it binds the same receptor.

It shows in preclinical models high affinity for the androgen receptor (Ki constant of ~3.8 nM) and tissue-selective activation profile: full anabolic agonism in skeletal muscle and bone tissue with minimal stimulation of the prostate. It is this separation of anabolic and androgenic profiles that is the central defining feature of the SARM class and the main reason for interest in ostarine in research.

The world of pharmacology is keeping an eye on MK-2866 for several reasons. First, as the most clinically documented SARM – with a Phase I-III program that has provided the broadest set of data on the pharmacokinetics and profile of this class in humans. Secondly, as a model ligand to study the tissue selectivity of the androgen receptor and the mechanisms of coregulator recruitment.

Third, as a tool in the study of sarcopenia, cachexia and bone metabolism – the indications for which this molecule was originally designed.

What is MK-2866 (Ostarine)?

Chemically, MK-2866 is a small non-steroidal molecule – arylpropionamide that binds the androgen receptor with high affinity.

  • Common name: MK-2866, Ostarine, Enobosarm
  • Research code: GTx-024 (S-22)
  • Pharmacological class: non-steroidal selective androgen receptor modulator (SARM); arylpropionamide; tissue-selective AR ligand
  • CAS number: 841205-47-8 (in case of uncertainty – “to be verified in the batch COA”)
  • Molecular formula: C₁₉H₁₄F₃N₃O₃ (to be verified in the batch COA)
  • Molar mass: ~389.33 g/mol (to be verified in the batch COA)
  • AR affinity: Ki ~3.8 nM (literature context – preclinical models)
  • Laboratory of Origin: GTx, Inc. (USA); Phase I–III clinical program for sarcopenia and cachexia
  • Delivered form: hard capsule, 10 mg of active substance per capsule, 60 capsules; pharmaceutical grade ≥98% HPLC

Table of physicochemical characteristics

Parameter Value Note
Name MK-2866, Ostarine, Enobosarm GTx-024, S-22
Chemical class arylpropionamide (small molecule non-steroidal) not a steroid, not a peptide
Pharmacological class selective androgen receptor modulator (SARM) tissue-selective AR ligand
CAS 841205-47-8 for verification in the batch COA
Molecular formula C₁₉H₁₄F₃N₃O₃ for verification in the batch COA
Molar mass ~389.33 g/mol for verification in the batch COA
Molecular target androgen receptor (AR), Ki ~3.8 nM tissue-selective agonism
Purity ≥98% HPLC UV detection, per batch verification
Form capsule, 10 mg/capsule, 60 capsules standardized sample
Selectivity profile agonism in muscle/bone, minimal activity in prostate anabolic-androgenic separation
Clinical status GTx program phase I–III (sarcopenia, cachexia) Phase III did not reach the primary endpoint
WADA status Prohibited List, Category S1.2 (other anabolic agents) banned continuously since 2008

Mechanism of action at the molecular level

MK-2866 works in research models by tissue-selective binding and activation of the androgen receptor. The following axes are described in the preclinical literature and the GTx clinical program. Pharmacological profile observed in research models:

  1. Selective androgen receptor (AR) binding. The best described mechanism of ostarine. As a non-steroidal arylpropionamide, the molecule binds the androgen receptor ligand domain with high affinity (Ki ~3.8 nM; Chen et al. 2005). The conformation of the ligand-receptor complex and the set of recruited coregulators differ from those induced by testosterone, which is the molecular basis of tissue selectivity – the primary, direct effect from which the remaining observations arise.
  2. Full anabolic agonism in skeletal muscle. In rodent models, MK-2866 behaves as a full AR agonist in muscle tissue – effects on anabolic markers and the increase in lean muscle mass were observed (Dalton et al. 2011, phase II). This is the direction that drives most of the research on the use of ostarine in sarcopenia and cachexia.
  3. Anti-resorption and anabolic profile in bone tissue. Preclinical models have described the effect of ostarine on bone metabolism – an AR agonist component in osteoblasts and an effect limiting bone resorption. This makes the molecule a tool in bone mineral density research alongside muscle anabolism.
  4. Minimal androgenic activity in the prostate (tissue selectivity). The central defining feature of the SARM class. In rodent models, MK-2866 shows significantly lower stimulation of prostate tissue than testosterone while maintaining muscle anabolism – this is the separation of anabolic and androgenic profiles for which the entire class was designed (Narayanan et al. 2008).
  5. Low suppression of the hypothalamic-pituitary-gonadal (HPG) axis compared to other SARMs. In the literature, ostarine is described as a compound with a relatively mild effect on the gonadal axis compared to stronger SARMs (RAD-140, LGD-4033). This is a comparative observation in models and clinical trials for a specific indication, not a declaration of no effect.
  6. No conversion to estrogens (no aromatization). As a non-steroidal arylpropionamide, MK-2866 is not an aromatase substrate – it is not subject to conversion to estrogens typical of testosterone and some steroids. This distinguishes the profile of the molecule from steroid androgens at the level of hormonal metabolism.

Important distinction - capsules vs. solution; ostarine and stronger SARMs

Understanding MK-2866’s position in the SARM catalog and map is the focal point of this description:

  • Capsule variant and 30 ml solution — the capsule variant contains a standardized powder weight (10 mg of active substance per capsule), which simplifies the handling of the reagent without an analytical balance. Solution variant, available in the catalog as MK-2866 liquid, declares the content as volumetric concentration (mg/ml). These are two formats for operating the same molecule – the choice depends on the methodology of a given research model; the identity and purity of both shall be decided by the party’s COA.
  • Tissue selectivity — MK-2866 is described as the SARM with the highest tissue selectivity in its class: it preserves muscle and bone anabolism with minimal activity in the prostate. This is the feature for which the SARM class was designed, and the reason for the widest clinical program around ostarine.
  • Ostarine and RAD-140 and LGD-4033 — RAD-140 (testolone) i LGD-4033 (ligandrol) are stronger SARMs with a stronger anabolic profile in models, but with a more pronounced effect on the gonadal axis and lower documented tissue selectivity towards ostarine. MK-2866 remains the benchmark in this class due to its breadth of clinical data.
  • Chemical class — MK-2866 is a non-steroidal arylpropionamide, not an anabolic-androgenic steroid or a peptide. It binds the androgen receptor, but it does not come from testosterone, it does not have a sterone ring and it does not aromatize to estrogens.

This distinction is of both mechanistic and compliance importance: ostarine is sometimes mistakenly classified as a “safer steroid”, while its pharmacology (non-steroidal AR ligand with tissue selectivity) is different. In anti-doping terms, however, it remains classified by WADA as an anabolic agent (S1.2) – regardless of its non-steroidal structure and selective profile.

Applications in scientific research

MK-2866 is used in research work in several areas. In vivo models (rat, mouse) examine its effect on lean muscle mass, anabolic markers, bone mineral density and tissue selectivity towards the prostate. In vitro models measure androgen receptor affinity, agonist/antagonist profile, and coregulator recruitment in various cell lines. Specific research directions include:

  • Tissue selectivity of AR ligands — MK-2866 as a model SARM in studies on the separation of muscle anabolism from androgenic activity in the prostate
  • Muscle anabolism and sarcopenia — research on the effect on lean body mass and anabolic markers, the direction of the original GTx clinical program; in this area, ostarine is sometimes combined with others SARMs for muscle mass in comparative analyses
  • Cancer cachexia — ostarine as a tool in models of muscle wasting associated with cancer (phase II/III program, including the POWER study)
  • Metabolism and bone density — analysis of the anabolic-anti-resorption profile in bone tissue
  • Comparative pharmacology of SARMs — MK-2866 in analyzes with RAD-140, LGD-4033, as well as with GW-501516 and MK-677 in terms of anabolism strength, selectivity and influence on the gonadal axis
  • Detection methods in anti-doping analysis — ostarine as an analyte in the development of SARM detection methods for WADA control

Summary

MK-2866 (ostarine, enobosarm, GTx-024; 10 mg × 60 capsules) is a non-steroidal selective androgen receptor modulator (SARM) from the arylpropionamide group, developed by GTx and tested in a phase I-III clinical program for sarcopenia and cachexia. This makes it the most clinically tested representative of the entire SARM class. Its central mechanism is tissue-selective androgen receptor binding (Ki ~3.8 nM): full anabolic agonism in muscle and bone with minimal androgenic activity in the prostate.

The models also described low suppression of the gonadal axis compared to stronger SARMs and no conversion to estrogens. MK-2866 is a small molecule non-steroidal (arylpropionamide), not a steroid and not a peptide, with the highest documented tissue selectivity in its class – different from the more potent but less selective RAD-140 and LGD-4033. The capsule variant (standardized dose of 10 mg) differs in format from the 30 ml solution variant.

HPLC purity ≥98%, MS Q-TOF, COA for each batch. Regulatory Status – Research Use Only; lack of EMA/FDA/EFSA authorization (phase III did not reach the primary endpoint); WADA Prohibited List, category S1.2 (other anabolic agents) continuously since 2008.

Bibliography

  1. Dalton JT, Barnette KG, Bohl CE, et al. (2011). The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women. PubMed
  2. Dobs AS, Boccia RV, Croot CC, et al. (2013). Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomized controlled phase 2 trial. PubMed
  3. Solomon ZJ, Mirabal JR, Mazur DJ, et al. (2019). Selective androgen receptor modulators: current knowledge and clinical applications. PubMed
  4. Narayanan R, Mohler ML, Bohl CE, et al. (2008). Selective androgen receptor modulators in preclinical and clinical development. PubMed
  5. Chen J, Kim J, Dalton JT (2005). Discovery and therapeutic promise of selective androgen receptor modulators. PubMed